AML: New Drugs but New Challenges
Despite the approval of 8 new drugs for AML since 2017, the disease remains challenging given the significant toxicity associated with available treatments and relatively low cure rates, especially in older adults. While advantageous for patients, self-congratulatory rejoicing about the new agents would be extremely premature. Questions abound about the need for a specific vs less specific FLT3 inhibitor (e.g midostautin) in the upfront setting and whether a single agent (gilteritnib), albeit better than chemotherapy is sufficient for relapsed disease. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 15, 2020 Category: Hematology Authors: Alan Burnett, Richard Stone Tags: Review Article Source Type: research

Corrigendum
to “Incidence of Silent Thrombosis in Patients Younger Than 60 Years With Myeloproliferative Neoplasms: Single-Center Egyptian Study” [Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):e425-429] (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 14, 2020 Category: Hematology Tags: Corrigendum Source Type: research

Tracing leukemia stem cells and its influence on clinical course of adult acute myeloid leukemia
This study aimed to demonstrate the impact of LSCs on MRD induction day (14) and Day (28) on overall survival (OS) and disease free survival (DFS) as well as compare it to MRD status. 84 De novo adult AML patients tested for LSCs panels CD38/CD123/CD34/CD45, CD90/CD133/CD45/CD33 as well as different regular MRD panels. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 13, 2020 Category: Hematology Authors: Eman Z. Kandeel, Nahla El Sharkawy, Marwa Hanafi, Mohamed Samra, Azza M. Kamel Tags: Original Study Source Type: research

RAS Pathway Mutation Patterns in Patients with Juvenile Myelomonocytic Leukemia; A developing country single center experience
Juvenile Myelomonocytic Leukemia (JMML) is a rare hematological malignancy. Developing countries are lagging behind in their facilities in molecular diagnostics. The bone marrow for 41 Egyptian children treated as JMML were retrospectively studied for RAS mutations. Mutations were detected in 80% of patients. Cancer centers in our region should start implementing molecular diagnostics before confirming the diagnosis of JMML. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 13, 2020 Category: Hematology Authors: Nayera Hamdy, Hossam Bokhary, Amr Elsayed, Walaa Hozayn, Sonya Soliman, Sherine Salem, Khaled Alsheshtawi, Amr Abdallah, Hanafy Hafez, Mahmoud Hammad Tags: Original Study Source Type: research

Analysis Of The Mortality Of Russian Patients With Chronic Myeloid Leukaemia In The Multicentre Eutos Eln Population-Based Study (Eutos-Pbs)
Russia took part in the multicenter population-based Study (Europe) and included 6.8% adult patients (pts) with newly diagnosed chronic myeloid leukemia (CML) (Hoffman V et al. 2016). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 13, 2020 Category: Hematology Authors: O.V. Lazareva, A.G. Turkina, E.Yu Chelysheva, A.A. Kulikovsky, M.A. Galayko, O.M. Senderova, V.M. Pepeliaeva, S.V. Meresiy, A.S. Luchinin, G.I. Milutina, L.V. Gavrilova, L.B. Avdeeva, E.B. Dasheeva, O.Yu Vinogradova, H.L. Julhakyan, S.M. Kulikov Tags: Current Trial Report Source Type: research

The triple positivity for ebv, pd-1 and pd-l1 identifies a very high risk classical hodgkin lymphoma
In this study, we aimed to investigate the effect of PD-1, PD-L1 and Ebstein Barr Virus (EBV) positivity on prognosis at the initial diagnosis of cHL. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 5, 2020 Category: Hematology Authors: Vedia Ozturk, Aysun Senturk Yikilmaz, Aydan Kilicarslan, Sule Mine Bakanay, Sema Akinci, İmdat Dilek Tags: Original Study Source Type: research

Burkitt Lymphoma presenting as cranial multineuritis secondary to Primary Neurolymphomatosis: a diagnostic challenge
Neurolymphomatosis (NL) is a devastating complication of non-Hodgkin Lymphoma (NHL) with significant morbidity. It was first described by Baehring et al in 2003 as the direct infiltration of the cranial and peripheral nervous systems by lymphoma cells (1). It is a rare clinical entity, affecting approximately 0.2% of all NHL patients (2). Most cases are due to B-cell NHL (3). Although typically a hallmark of disease progression, it can also be the presenting symptom of a new diagnosis. When this occurs, it is referred to as “Primary NL” (1). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 4, 2020 Category: Hematology Authors: Lindsey Fitzgerald, Deborah M. Stephens Tags: Case Report Source Type: research

Early Relapse post Autologous Transplant is Associated With Very Poor Survival and Identifies an Ultra High Risk Group of Myeloma Patients
Myeloma patients that relapse early, within less than 12 months, after an autologous stem cell transplantation have a very poor outcome with a median post-transplant survival of just 18 months. Their outcome has not improved significantly over time. These myeloma patients relapsing early after transplant comprise an ultra-high risk group that urgently needs more effective therapies. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 3, 2020 Category: Hematology Authors: Efstathios Kastritis, Maria Roussou, Evangelos Eleutherakis-Papaiakovou, Maria Gavriatopoulou, Magdalini Migkou, Dimitra Gika, Despina Fotiou, Nikolaos Kanellias, Dimitrios C. Ziogas, Ioannis Ntanasis-Stathopoulos, Despoina Mparmparousi, Anastasia Gatou, Tags: Original Study Source Type: research

Survival of older adults with newly diagnosed acute myeloid leukemia: Effect of using multiagent versus single agent chemotherapy
We analyzed US National Cancer Data Base of patients aged 60-79 years, who were diagnosed with acute myeloid leukemia (AML) between 2004-2014 (n=25,621). The use of multiagent versus single-agent chemotherapy was associated with a greater 1-year overall survival (43% vs. 28%), particularly for patients aged 60-69 years, those with good-risk AML or Charlson comorbidity score of 0-1. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 3, 2020 Category: Hematology Authors: Vijaya R. Bhatt, Valerie Shostrom, Sarah A. Holstein, Zaid S. Al-Kadhimi, Lori J. Maness, Ann Berger, James O. Armitage, Krishna Gundabolu Tags: Original Study Source Type: research

Case report: Carfilzomib induced Thrombotic Microangiopathy with complement activation treated successfully with Eculizumab.
Thrombotic Microangiopathy (TMA) is a group of disorders characterized by endothelial injury leading to activation of coagulation cascade, consumptive coagulopathy, thrombocytopenia and hemolytic anemia. TMA causes end organ damage such as renal and central nervous system dysfunction related to small vessel thrombosis and resultant ischemia (1). The pathogenesis of TMA is primarily divided into four major pathways a) autoantibody against ADAMTS13 leading to TTP (thrombotic thrombocytopenic purpura), b) atypical HUS (hemolytic uremic syndrome) mediated by complement activation related to inherited mutations in the complemen...
Source: Clinical Lymphoma, Myeloma and Leukemia - February 3, 2020 Category: Hematology Authors: D. Bhutani, A. Assal, M.Y. Mapara, S. Prinzing, S. Lentzsch Tags: Case Report Source Type: research

Consensus Guidelines on the Diagnosis of Multiple Myeloma and Related Disorders Myeloma Canada Research Network Consensus Guideline Consortium Recommendations
Multiple myeloma (MM) is a plasma cell (PC) malignancy of terminally differentiated B lymphocytes that is typically associated with the secretion of partial and/or complete monoclonal immunoglobulins and a constellation of particular symptoms and signs. MM is a treatable condition and timely diagnosis is essential to limit or avoid irreversible target-organ damage and to prolong survival.The Myeloma Canada Research Network Consensus Guideline Consortium (MCRN-CGC) proposes national consensus recommendations for the diagnosis of MM and associated PC neoplasms. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 3, 2020 Category: Hematology Authors: Myeloma Canada Research Network Consensus Guideline Consortium (alphabetical order), Debra J. Bergstrom, Rami Kotb, Martha L. Louzada, Heather J. Sutherland, Sofia Tavoularis, Christopher P. Venner Tags: Review Article Source Type: research

18F-FDG PET or PET/CT in Mantle Cell Lymphoma.
The aim of this systematic review was to examine published data about the potential role of Fluorine-18-fluorodeoxyglucose positron emission tomography or positron emission tomography/computed tomography (18F-FDG PET or PET/CT) in patients affected by mantle cell lymphoma (MCL). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 3, 2020 Category: Hematology Authors: Domenico Albano, Giorgio Treglia, Marina Gazzilli, Elisabetta Cerudelli, Raffaele Giubbini, Francesco Bertagna Tags: Review Article Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 1, 2020 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 1, 2020 Category: Hematology Source Type: research

Does outcome/survival of patients with myelodysplastic syndromes should be predicted by reduced levels of adamts-13? results from a pilot study.
Von Willebrand factor (vWF) cleaving protease ADAMTS-13 has a key role for maintaining normal size of vWF. A deficiency or dysfunction of vWF cleaving protease is associated with ultra large vWF multimers and thrombotic microangiopathy (TMA). Patients with cancers have reduced levels of vWF cleaving protease. In this pilot study we have evaluated whether or not deficiencies of ADAMTS-13 were present in myelodysplastic syndromes (MDS). Moreover, we assessed if a reduction in basal levels of ADAMTS-13 may play a role in the prognosis of MDS. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 30, 2020 Category: Hematology Authors: Roberto Castelli, Luigi Bergamaschini, Thomas Teatini, Luca Cilumbriello, Riccardo Schiavon, Paolo Gallipoli, Giorgio Lambertenghi Delilies Tags: Original Study Source Type: research

A User ’s Guide to Novel Therapies for Acute Myeloid Leukemia
Few diseases have been marked by a 40-year period of stagnation with regards to therapeutic advances and Food& Drug Administration (FDA) approvals, as has been the case for acute myeloid leukemia (AML). Cytarabine and anthracyclines were introduced for the treatment of AML in the 1970s, and in the ensuing four decades, the pharmacologic pipeline has experienced a standstill. The absence of FDA approvals in AML is not a reflection of the lack of understanding of the disease biology. The field has seen major advances from the standpoint of stem cell biology and clonal evolution, and the field has also seen some therapeut...
Source: Clinical Lymphoma, Myeloma and Leukemia - January 30, 2020 Category: Hematology Authors: Shyam A. Patel, Jonathan M. Gerber Tags: Review Article Source Type: research

Successful Treatment of Paraneoplastic Cholestasis in Relapsed/Refractory Hodgkin ’s Lymphoma with Bridging Therapy and Checkpoint Blockade
Paraneoplastic cholestasis is a rare manifestation of Hodgkin ’s lymphoma (HL), especially in the relapsed/refractory setting. Outcomes are generally poor, perhaps related to the narrow therapeutic window of standard chemotherapy drugs in patients with compromised liver function and limited activity of radiotherapy in controlling systemic disease. Here, we p resent the first report of successful treatment of a patient with idiopathic cholestasis in the setting of relapsed HL post autologous stem cell transplant (ASCT) with bridging therapy (cyclophosphamide, methylprednisolone) and sequential nivolumab. (Source: Clin...
Source: Clinical Lymphoma, Myeloma and Leukemia - January 29, 2020 Category: Hematology Authors: Gopisree Peringeth, Pallawi Torka, Jerry Wong, Francisco J. Hernandez-Ilizaliturri Tags: Case Report Source Type: research

Effect of the Thiotepa dose in the TBF Conditioning regimen in Patients Undergoing Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia in complete remission: A report from the EBMT Acute Leukemia Working Party
This study suggested that a lower dose-intensity of thiotepa and busulfan (5 mg/kg thiotepa and 2 days of iv busulfan at 6.4 mg/kg (T1B2F) in the TBF regimen may yield better outcomes. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 27, 2020 Category: Hematology Authors: Jean El-Cheikh, Myriam Labopin, Farouk Al-Chami, Ali Bazarbachi, Emanuele Angelucci, Stella Santarone, Francesca Bonifazi, Angelo Michele Carella, Luca Castagna, Benedetto Bruno, Anna Paola Iori, Giorgio La Nasa, Bipin Savani, Arnon Nagler, Mohamad Mohty Tags: Original Study Source Type: research

Comparable Efficacy and Safety of Generic Imatinib and Branded Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukaemia with a Consideration of Socio-economic Characteristics: A Retrospective Study from a Single Centre
To compare the efficacy and safety of generic and branded imatinib in adults with newly diagnosed chronic myeloid leukaemia in the chronic phase (CML-CP), we retrospectively reviewed data from patients CML-CP receiving generic or branded imatinib. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 27, 2020 Category: Hematology Authors: Xuelin Dou, Yazhen Qin, Yueyun Lai, Hongxia Shi, Xiaojun Huang, Qian Jiang Tags: Original Study Source Type: research

Graft-versus-host disease in multiple myeloma patients treated with daratumumab after allogeneic transplantation
Decrease in regulatory T cell (Tregs) has been linked to GVHD after alloHCT. The use of daratumumab poses a theoretical concern for GVHD flare because of its effects on Tregs and helper and cytotoxic T cells. In this multicenter, retrospective study of relapsed multiple myeloma patients, who received daratumumab after alloHCT, we demonstrate low incidence of GVHD after daratumumab treatment. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 27, 2020 Category: Hematology Authors: Liana Nikolaenko, Saurabh Chhabra, Noa Biran, Arnab Chowdhury, Parameswaran N. Hari, Amrita Krishnan, Joshua Richter Tags: Original Study Source Type: research

Cardiotoxicity in Hematopoietic Stem Cell Transplant: Keeping the Beat
This study describes the incidence and type of cardiac events (CE) experienced by autologous and allogeneic hematopoietic stem cell transplant patients over a five-year period at one institution. 9.8% of patients experienced a CE, and those that experienced a CE had an increased risk of death within one year (p (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 17, 2020 Category: Hematology Authors: Julie Kay Baker, Jessica Shank-Coviello, Bin Zhou, Jane Dixon, Ruth McCorkle, Daniel Sarpong, Erin Medoff, Dennis Cooper, Stuart Seropian, Feng Dai Tags: Original Study Source Type: research

SF3B1 Mutation but Not Ring Sideroblasts Identifies a Specific Group of Myelodysplastic Syndrome –Refractory Cytopenia With Multilineage Dysplasia
To investigate the clinical implications of SF3B1 and ring sideroblasts in myelodysplastic syndrome –refractory cytopenia with multilineage dysplasia (MDS-RCMD), 238 consecutive MDS-RCMD patients were studied. SF3B1 mutation in MDS-RCMD patients identified a homogenous phenotype characterized by homogeneous hematologic features, including a high prevalence of erythroid dysplasia and a high propo rtion of ring sideroblasts, prolonged survival, and reduced leukemic transformation. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 16, 2020 Category: Hematology Authors: Bei Xiong, Mei Xue, Yalan Yu, Sanyun Wu, Xuelan Zuo Tags: Original Study Source Type: research

SF3B1 mutation but not ring sideroblasts identifies a specific group of myelodysplastic syndrome-refractory cytopenia with multilineage dysplasia
To investigate the clinical implications of SF3B1 and ring sideroblasts in myelodysplastic syndrome-refractory cytopenia with multilineage dysplasia (MDS-RCMD), 238 consecutive MDS-RCMD patients were included in this study. Our results showed that SF3B1 mutation in MDS- RCMD patients identifies a homogenous phenotype characterized by homogeneous hematologic features including a high prevalence of erythroid dysplasia and a high proportion of ring sideroblasts, prolonged survival and reduced leukemic transformation. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 16, 2020 Category: Hematology Authors: Bei Xiong, Mei Xue, Yalan Yu, Sanyun Wu, Xuelan Zuo Tags: Original Study Source Type: research

Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study
Patients with multiple myeloma (MM) who experience deep remissions, including minimal residual disease (MRD) negativity, have better clinical outcomes compared to those do not. We aimed to describe the effect of testing for MRD negativity in a cohort of MM patients outside of a clinical trial. For most patients, MRD negativity supports improved clinical outcomes. However, in our cohort of patients with high-risk MM, MRD negativity does not seem to affect the overall poor prognosis. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 15, 2020 Category: Hematology Authors: Chutima Kunacheewa, Hans C. Lee, Krina Patel, Sheeba Thomas, Behrang Amini, Samer Srour, Qaiser Bashir, Yago Nieto, Muzzaffar H. Qazilbash, Donna M. Weber, Lei Feng, Robert Z. Orlowski, Pei Lin, Elisabet E. Manasanch Tags: Original Study Source Type: research

Minimal residual disease negativity does not overcome poor prognosis in high risk multiple myeloma: a single center retrospective study
Minimal residual disease (MRD) is a standard measurement for response assessment in multiple myeloma (MM). Despite new treatments, high-risk MM patients continue to have poor prognosis. We evaluated the impact of MRD- in high vs standard- risk patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 15, 2020 Category: Hematology Authors: Chutima Kunacheewa, Hans C. Lee, Krina Patel, Sheeba Thomas, Amini Behrang, Samer Srour, Qaiser Bashir, Yago Nieto, Muzzaffar H. Qazilbash, Donna M. Weber, Lei Feng, Robert Z. Orlowski, Pei Lin, Elisabet E. Manasanch Tags: Original Study Source Type: research

Decoding Bone Marrow Fibrosis in Myelodysplastic Syndromes
We examined the relationship between bone marrow fibrosis (BMF) in myelodysplastic syndromes and survival outcomes, and somatic gene mutations in the setting of BMF. Grade 3 BMF was associated with reduced overall survival; however, BMF grade did not affect response to hypomethylating agent or lenalidomide treatment. Complex karyotype, higher bone marrow myeloblasts, lower platelets, and higher rate of elevated lactate dehydrogenase were more often observed in patients with severe BMF. TP53  mutation and SETBP1 were more frequent in patients with grade 3 BMF. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 14, 2020 Category: Hematology Authors: Megan Melody, Najla Al Ali, Ling Zhang, Hanadi Ramadan, Eric Padron, David Sallman, Kendra Sweet, Jeffrey Lancet, Alan List, John M. Bennett, Rami Komrokji Tags: Original Study Source Type: research

Hepatitis C Virus-associated Lymphoplasmacytic Lymphoma With Waldenstr öm Macroglobulinemia: Response to Direct-acting Antiviral Therapy
Lymphoplasmacytic lymphoma (LPL) with or without Waldenstr öm macroglobulinemia (WM) is a rare lymphoproliferative disorder (LPD) characterized by the presence of monoclonal immunoglobulin M (IgM) paraproteinemia and bone marrow (BM) infiltration by small lymphocytes with plasmacytoid or plasma cell differentiation.1 LPL/WM constitutes less than 5% of all non-Hodgkin lymphomas (NHLs) and 1% to 2% of hematologic malignancies.2 Patients with LPL/WM may be initially asymptomatic (smoldering WM), but over the course of their disease, they may present with fatigue, shortness of breath, anemia, lymphadenopathy (LAD), spleno...
Source: Clinical Lymphoma, Myeloma and Leukemia - January 14, 2020 Category: Hematology Authors: Yenny Alejandra Moreno Vanegas, Ridas Juskevicius, Bhagirathbhai Dholaria Tags: Case Report Source Type: research

Decoding Bone Marrow Fibrosis in Myelodysplastic Syndrome
The presence of grade 3 BMF is associated with reduced OS independent from IPSS-R; however, BMF grade did not impact response to hypomethylating agent or lenalidomide treatment. TP53 and SETBP1 mutations occurred with greater frequency among patients with severe fibrosis. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 14, 2020 Category: Hematology Authors: Megan Melody, Najla Al Ali, Ling Zhang, Hanadi Ramadan, Eric Padron, David Sallman, Kendra Sweet, Jeffrey Lancet, Alan List, John M. Bennett, Rami Komrokji Tags: Original Study Source Type: research

Hepatitis C virus associated lymphoplasmacytic lymphoma with Waldenstr ӧm macroglobulinemia: response to direct-acting antiviral therapy
Lymphoplasmacytic lymphoma (LPL) with or without Waldenstr ӧm macroglobulinemia (WM) is a rare lymphoproliferative disorder (LPD) characterized by the presence of monoclonal immunoglobulin M (IgM) paraproteinemia and bone marrow (BM) infiltration by small lymphocytes with plasmacytoid or plasma cell differentiation.1 LPL/WM constitutes less than 5% of all non-Hodgkin lymphomas (NHLs) and 1-2% of hematological malignancies.2 Patients with LPL/WM may be initially asymptomatic (smoldering WM) but over the course of their disease they may present with fatigue, shortness of breath, anemia, lymphadenopathy (LAD), splenomegaly a...
Source: Clinical Lymphoma, Myeloma and Leukemia - January 14, 2020 Category: Hematology Authors: Yenny Alejandra Moreno Vanegas, Ridas Juskevicius, Bhagirathbhai Dholaria Tags: Case Report Source Type: research

Bacterial Infection Among Patients With Multiple Myeloma Treated With Bortezomib-based Induction Therapy: Real-World Experience in an Asian Cancer Center
In an evaluation of 108 newly diagnosed patients with myeloma treated with bortezomib-based induction therapy with adequate access to health care facilities and timely supportive care, without routine fluoroquinolone prophylaxis, but with routine Pneumocystis Carinii prophylaxis (mostly with trimethoprim-sulfamethoxazole), the proportion of patients with significant bacterial infection is low. We also showed that low absolute neutrophil count, International Staging System stage, and renal impairment are associated with increased risk of febrile episodes. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 9, 2020 Category: Hematology Authors: Cinnie Yentia Soekojo, Jia Zhen Low, Jaslyn Oh, Melissa Ooi, Sanjay De Mel, Wee Joo Chng Tags: Original Study Source Type: research

Title: SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes
Immunosuppressive therapy (IST) yields durable hematologic improvement (HI) in a subset of patients with lower risk myelodysplastic syndrome (MDS). We investigated the impact of somatic gene mutations on response to IST in lower risk MDS. Among 40 patients evaluated by NGS, the presence of an SF3B1 mutation (MT) was significantly associated with IST nonresponse (1 of 9 SF3B1 MT, 11% vs. 21 of 31 wild type (WT), 68%; p=0.002). In multivariable analysis, combination with cyclosporine, no prior hypomethylating and absence of SF3B1 MT were predictive of response (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 9, 2020 Category: Hematology Authors: Qing Zhang, Mintallah Haider, Najla H. Al Ali, Jeffrey E. Lancet, Pearlie K. Epling-Burnette, Alan F. List, Eric Padron, Rami S. Komrokji Tags: Original Study Source Type: research

Bacterial Infection Amongst Multiple Myeloma Patients Treated With Bortezomib- Based Induction Therapy: Real-World Experience in an Asian Cancer Center
In an evaluation of 108 newly-diagnosed myeloma patients treated with bortezomib-based induction therapy with adequate access to healthcare facilities and timely supportive care, without routine fluoroquinolone prophylaxis, but with routine Pneumocystis Carinii prophylaxis (mostly with trimethoprim-sulfamethoxazole), the proportion of patients with significant bacterial infection is low. We also showed that low absolute neutrophil count, ISS stage, and renal impairment are associated with increased risk of febrile episodes. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 9, 2020 Category: Hematology Authors: Cinnie Yentia Soekojo, Jia Zhen Low, Jaslyn Oh, Melissa Ooi, Sanjay De Mel, Wee Joo Chng Tags: Original Study Source Type: research

Vitiligo Following Autologous Hematopoietic Stem Cell Transplantation
In this report, we describe a case of significant hypopigmentation consistent with vitiligo, developing in a patient with multiple myeloma following autologous HSCT. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 9, 2020 Category: Hematology Authors: James Nguyen, Navdeep Singh, Salma Afifi, Sergio Giralt, Mario E. Lacouture, Klaus J. Busam, Hani Hassoun Tags: Case Report Source Type: research

High Incidence of Clonal CD8+ T-cell Proliferation in Non-malignant Conditions May Reduce the Significance of T-cell Clonality Assay for Differential Diagnosis in Oncohematology
The objective of this study was to evaluate the specificity and positive predictive value of PCR-based clonality assessment for a differential diagnostics of T-LGL leukemia. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 8, 2020 Category: Hematology Authors: Yulia V. Sidorova, Kseniya A. Sychevskaya, Nataliya G. Chernova, Hunan L. Julhakyan, Svetlana Ju. Smirnova, Nataliya V. Ryzhikova, Vadim R. Gorodetskiy, Elena V. Naumova, Andrey B. Sudarikov Tags: Review Source Type: research

Survival of Patients with Second Primary Hodgkin Lymphoma
The outcomes of patients with a second primary Hodgkin lymphoma after an antecedent malignancy have never been described. We used cancer registry data to compare survival between 821 patients with second primary Hodgkin lymphoma and 31,355 patients with first primary Hodgkin lymphoma. We found that survival outcomes were worse in the second primary Hodgkin lymphoma group, a novel finding. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 8, 2020 Category: Hematology Authors: Justin Budnik, Christopher Doucette, Michael T. Milano, Louis S. Constine Tags: Original Study Source Type: research

Adequate Engraftment with Lower Hematopoietic Stem Cell Dose
Data for 108 patients with multiple myeloma and lymphoma who received a stem cell dose less than 2 x 106/kg with those who received higher dose was compared.Neutrophil engraftment, platelet engraftment, length of hospital stay and incidence of proven bacterial infections were similar in both groups. ASCT can be safely performed even with lower HSC dose in non-cryopreserved setting. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 8, 2020 Category: Hematology Authors: Preethi Jeyaraman, Pronamee Borah, Nitin Dayal, Sangeeta Pathak, Rahul Naithani Tags: Original Study Source Type: research

SOHO State of the Art Updates and Next Questions: Withdrawal Syndrome after Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myeloid Leukemia in the Russian Prospective Study RU-SKI
Nighty-eight chronic myeloid leukemia (CML) patients were included in the prospective clinical study RU-SKI and discontinued tyrosine kinase inhibitor (TKI) therapy. Withdrawal syndrome (WS) was found in 41 (42%) patients with a median time of observation of 25 months. Older age and longer TKI therapy were associated with WS. We found no relation between the rate of molecular relapses and WS. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 8, 2020 Category: Hematology Authors: Anna Petrova, Ekaterina Chelysheva, Oleg Shukhov, Anastasiya Bykova, Irina Nemchenko, Galina Gusarova, Nikolay Tsyba, Hunan Julhakyan, Vasiliy Shuvaev, Mikhail Fominykh, Irina Martynkevich, Tatyana Ionova, Anna Turkina Tags: Current Trial Report Source Type: research

SOHO State of the Art Updates and Next Questions: High incidence of clonal CD8+ T-cell proliferation in non-malignant conditions may reduce the significance of T-cell clonality assay for differential diagnosis in oncohematology
The presence of clonal CD8+CD57+ cells in blood is common for healthy individuals and patients with reactive conditions and may not associate with any malignancy. T-cell monoclonality cannot perceive as an exclusive argument in favor of T-LGL leukemia diagnosis. Different levels of specificity for certain TCRG/ D β-Jβ TRB/ Vβ-Jβ TCRB PCR reactions should be taken into account for accurate T-cell clonality data interpretation. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 8, 2020 Category: Hematology Authors: Yulia V. Sidorova, Kseniya A. Sychevskaya, Nataliya G. Chernova, Hunan L. Julhakyan, Svetlana Ju. Smirnova, Nataliya V. Ryzhikova, Vadim R. Gorodetskiy, Elena V. Naumova, Andrey B. Sudarikov Tags: Current Trial Report Source Type: research

Daratumumab-Based Regimen in Treating Clonal Plasma Cell Neoplasms in Solid Organ Transplant Recipients
There is paucity of literature regarding management of clonal plasma cell neoplasms in the recipients of solid organ transplant. This is a rare group of disorders which present difficulty in diagnosis and management. In this retrospective case series, we describe the clinical and pathologic characteristics of patients with AL amyloidosis and extramedullary plasmacytoma in recipients of solid organ transplant while on immunosuppressive therapy. Although typically treated with anti-plasma cell therapy based on data from multiple myeloma studies, there is no consensus on how to treat this group of disorders in the post-solid ...
Source: Clinical Lymphoma, Myeloma and Leukemia - January 8, 2020 Category: Hematology Authors: Chakra P. Chaulagain, Julia M. Diacovo, Leah Elson, Raymond L. Comenzo, Christy Samaras, Faiz Anwer, Jack Khouri, Heather Landau, Jason Valent Tags: Case Report Source Type: research

Donor Lymphocyte Infusions After Allogeneic Transplantation: A Single-Center Experience
Allogeneic hematopoietic cell transplantation (AHCT) represents the only curative therapy for many hematological malignancies. The graft versus leukemia effect, driven by donor T cells, plays a major role in its curative potential. This effect is sometimes very evident when patients with acute myeloid leukemia and myelodysplasia relapse after AHCT and are treated with donor lymphocyte infusions (DLIs). We retrospectively reviewed the charts of 64 patients who received DLI between 2012 and 2017 in our center. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 2, 2020 Category: Hematology Authors: Fouad Kerbage, Riwa Sakr, Valerie Lapierre, Kamelia Alexandrova, Tereza Coman, Severine Leroux, Nolwenn Lucas, Sylvain Pilorge, Eric Solary, Jean-henri Bourhis, Cristina Castilla-Llorente Tags: Review Source Type: research

Dual Monoclonal Antibody Therapy in Patients with Systemic AL Amyloidosis and Cardiac Involvement
Combining dual antibody therapy with daratumumab and NEOD001 (birtamimab) for treatment of AL cardiac amyloidosis is safe and results in quick hematologic and organ responses. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 2, 2020 Category: Hematology Authors: Amandeep Godara, Nauman Siddiqui, Lisa X. Lee, Denis Toskic, Teresa Fogaren, Cindy Varga, Raymond L. Comenzo Tags: Original Study Source Type: research

Donor Lymphocyte Infusions after Allogeneic Transplantation: A Single Center Experience
Allogeneic hematopoietic cell transplantation (AHCT) represents the only curative therapy for many haematological malignancies. The graft-versus-leukemia effect (GVL), driven by donor Tcells plays a major role in its curative potential. This effect is sometimes very evident when AML and MDS relapses post AHCT are treated with donor lymphocyte infusions (DLI), in which lymphocytes from the original stem cell donor are infused, to augment an anti-tumor immune response or ensure that the donor stem cells remain engrafted, after the transplant. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 2, 2020 Category: Hematology Authors: Fouad Kerbage, Riwa Sakr, Valerie Lapierre, Kamelia Alexandrova, Tereza Coman, Severine Leroux, Nolwenn Lucas, Sylvain Pilorge, Eric Solary, Jean-henri Bourhis, Cristina Castilla-Llorente Tags: Review Article Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 1, 2020 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 1, 2020 Category: Hematology Source Type: research

Outcome of Imatinib treatment in Yemeni patients with chronic myeloid leukemia and the influence of non-adherence to treatment and duration of prior hydroxyurea therapy
In a developing country like Yemen, data are limited regarding the outcome of Imatinib treatment of chronic myeloid leukemia and the impact of non-adherence to Imatinib and prior duration of hydroxyurea. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 31, 2019 Category: Hematology Authors: Jameel Al-Ghazaly, Waled Al-Dubai, Yousr Noaman, Munasser Abdullah, Leila Al-Gharasi, Gianantonio Rosti Tags: Original Study Source Type: research

Effect of Exposure to Agent Orange (AO) on the Risk of Monoclonal Gammopathy and Subsequent Transformation to Multiple Myeloma (MM): A Single Center Experience from VA Hospital, Detroit
Monocloncal gammopathy of undermined significance (MGUS) is an indolent, pre-malignant plasma cell disorder with the potential of transforming into symptomatic multiple myeloma. There are multiple risk factors contributing to transformation. Agent Orange (AO) has been linked with multiple malignant and non-malignant conditions. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 27, 2019 Category: Hematology Authors: Naresh Bumma, Misako Nagasaka, Griffin Hemingway, Hirotaka Miyashita, Tahmida Chowdhury, Seongho Kim, Hema M. Vankayala, Shabbir Ahmed, Pallavi Jasti Tags: Original Study Source Type: research

Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Selinexor, an orally bioavailable, first-in-class selective inhibitor of nuclear export, was United States Food and Drug Administration-approved in combination with dexamethasone for patients with penta-refractory multiple myeloma in July 2019. The United States Food and Drug Administration approval was based on results from 83 patients on the phase IIb STORM study, which showed an overall response rate (ORR) of 25% and a median duration of response of 3.8 months.1 Selinexor has been combined with bortezomib2 and carfilzomib. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 26, 2019 Category: Hematology Authors: Meghan Salcedo, Nikoletta Lendvai, Donna Mastey, Julia Schlossman, Malin Hultcrantz, Neha Korde, Sham Mailankody, Alexander Lesokhin, Hani Hassoun, Eric Smith, Urvi Shah, Victoria Diab, Kelly Werner, Heather Landau, Oscar Lahoud, Pamela Drullinsky, Gunjan Tags: Letter to the Editor Source Type: research

Immune-related Adverse Events Associated With Checkpoint Inhibition in the Setting of CAR T Cell Therapy: A Case Series
CD19-directed chimeric antigen receptor (CAR) T cell therapy is a very promising and effective therapy for relapsed or refractory aggressive B cell lymphomas.1,2 However, approximately 60% to 70% of patients with aggressive B cell lymphoma do not achieve a durable remission.3 One major mechanism of resistance to CAR T cell therapy is the limited persistence of CAR T cells after infusion. This could be partly mediated by the upregulation of programmed cell death protein 1 (PD-1) expression on CAR T cells leading to immune exhaustion and subsequent disease relapse. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 26, 2019 Category: Hematology Authors: Swetha Kambhampati, Lissa Gray, Bita Fakhri, Mimi Lo, Khoan Vu, Shagun Arora, Lawry Kaplan, Weiyun Z. Ai, Charalambos Andreadis Tags: Case Report Source Type: research

Phase I study of selinexor, ixazomib and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma
Selinexor, an orally bioavailable, first in class selective inhibitor of nuclear export (XPO1), was FDA approved in combination with dexamethasone for penta-refractory multiple myeloma patients in July 2019. The FDA approval was based on results from 83 patients on the Phase 2b STORM study that showed an ORR of 25% and a median duration of response of 3.8 months (1). Selinexor has been combined with bortezomib (2) and carfilzomib (3). Based on early results suggesting possible synergistic activity between selinexor and proteasome inhibitors, we designed a Phase I study to evaluate an all-oral combination therapy using the ...
Source: Clinical Lymphoma, Myeloma and Leukemia - December 26, 2019 Category: Hematology Authors: Meghan Salcedo, Nikoletta Lendvai, Donna Mastey, Julia Schlossman, Malin Hultcrantz, Neha Korde, Sham Mailankody, Alexander Lesokhin, Hani Hassoun, Eric Smith, Urvi Shah, Victoria Diab, Kelly Werner, Heather Landau, Oscar Lahoud, Pamela Drullinsky, Gunjan Tags: Letter to the Editor Source Type: research

Immune Related Adverse Events Associated with Checkpoint Inhibition in the Setting of CAR T-Cell Therapy: A Case Series
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy leads to high overall response rates of ∼80% even in heavily pre-treated diffuse large B-cell lymphoma (DLBCL), though relapse-free survival drops to ∼40% within the first 12 months. There are early data suggesting that inhibiting the programmed cell death protein 1: programmed cell death ligand 1 (PD-1: PD-L1) checkpoint axis may dec rease T cell exhaustion and improve CAR T-cell function. However, there is limited data regarding the toxicity of sequencing these two modalities. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 26, 2019 Category: Hematology Authors: Swetha Kambhampati, Lissa Gray, Bita Fakhri, Mimi Lo, Khoan Vu, Shagun Arora, Lawry Kaplan, Weiyun Z. Ai, Charalambos Andreadis Tags: Case Report Source Type: research